MT-UAVIONIX
8.4.2021 03:37:10 CEST | Business Wire | Press release
Today, uAvionix, the leader in communications, navigation, and surveillance (CNS) solutions for Unmanned Aircraft Systems (UAS), announced ping200X , its flagship Mode S ADS-B OUT Transponder for UAS, has received Technical Standard Order (TSO) certification from the FAA. ping200X is the pinnacle of years of evolution and investment in groundbreaking, low-Size, Weight, and Power (SWaP) avionics developed by uAvionix – certified for use on civil and defense manned and unmanned aircraft.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210407006039/en/
Weighing only 50 grams, ping200X delivers 200 watts of transmit power while only drawing an average of 1.5 watts from the aircraft's power supply. Its profile enables longer flight times and larger payloads with minimal energy consumption. When paired with truFYX , uAvionix’s SBAS GPS, ping200X meets the requirements of global controlled airspace, delivering safe separation information to Air Traffic Control (ATC), Traffic Collision Avoidance Systems (TCAS), and Detect and Avoid (DAA) systems.
ADS-B and transponder technology is a key component of UAS integration for mixed-use airspace. The FAA’s recent ruling on remote identification for UAVs establishes that Part 21 certificated aircraft must be equipped with a Remote ID device and/or ADS-B OUT Transponder for legal operations. Additionally, the FAA's Concept of Operations for Upper-Class E Traffic Management (ETM) includes ADS-B and Mode S Transponders as key technologies enabling coordination in the upper atmosphere.
ping200X integrates and combines a Mode S Transponder, ADS-B OUT, and an altitude encoder certified to the following TSOs:
- TSO-C112e (Mode S Transponder)
- TSO-C166b (ADS-B OUT Extended Squitter)
- TSO-C88b (altitude encoder)
“Certified avionics ensure the systems perform to the same high standards that have allowed aviation to remain the safest form of transportation for decades,” said Christian Ramsey, President. “This is even more important for systems like transponders and ADS-B which interact with other airspace users. Regulators and ANSPs demand the design assurance and quality assurance that a TSO offers to ensure safe separation of aircraft.”
The ping200X is integrable with many popular onboard UAS autopilots for dynamic control from ground control stations (GCS). ping200X can also be pre-configured before flight and carried as a payload. Replicating the functionality of a cockpit transponder controller, the uAvionix mini-controller allows you to dial-in a squawk code before takeoff for even quicker integration and rapid deployment.
To learn more about ping200X or to request a quote, visit uAvionix.com/products/ping200X/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210407006039/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 16:44:00 CET | Press release
One SKU. Every market. Connectivity decided at the end of production. Live at electronica 2026. Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the pr
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom